BackRevance Therapeutics Overview

Revance Therapeutics Selling, General & Admin

Selling, General & Admin expenses for RVNC.

Quarterly SG&A Expenses

$62.22M
↓ 8.14% YoY

As of Sep 30, 2024

Annual SG&A Expenses (TTM)

$279.41M
↑ 1.1% YoY

Trailing 12 months ending Sep 30, 2024

Average SG&A Expenses (Comparison Companies)

Selling, General & Admin History

Selling, General & Admin Comparison

Annual Selling, General & Admin Growth Rate (%)

Annual Selling, General & Admin Growth (Absolute)

Jump to metric
Total RevenueCost of RevenueGross ProfitResearch & DevelopmentSelling, General & AdminOperating IncomeOther Income Expense NetEBITIncome TaxNet IncomeProfit Margin